Branch retinal vein occlusion
Conditions
Interventions
Patients treated with faricimab :None
Sponsors
The First People's Hospital of XuZhou
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Reached the age of 18 when signing the informed consent form; 2. Patients diagnosed with branch retinal vein occlusion; 3. Decided to receive faricimab; 4. Has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who did not receive faricimab; 2. Patients who failed to provide valid data from ultra-wide-angle fluorescence angiography (UWFFA) within 2 weeks (14 days) prior to the initial faricimab injection; 3. Patients whose eyes had received any faricimab or intravitreal anti-VEGF drug and long-acting corticosteroid (including ranibizumab, aflibercept, conbercept, etc.) treatment before the study; 4. Patients who participated in other ocular clinical trials within 28 days prior to enrollment; 5. Other situations deemed unsuitable for participation in this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual acuity;leakage index ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Central retinal subfield thickness, CST;Macular OCT (Optical Coherence Tomography); | — |
Countries
China
Contacts
Public ContactLi Suyan
The First People's Hospital of XuZhou
Outcome results
None listed